saudi Arabia NGS Market Trends
Meticulous Research®, a leading global market research firm, has published a research report titled " Saudi Arabia Next Generation Sequencing (NGS) Market Size, Share, Forecast, and Trends Analysis by Offering (Sample Preparation (DNA Extraction, Library Preparation), Instruments) Type (SMRT, DNB) Application (Clinical, Research) End User-Forecast to 2031." According to the newest Meticulous Research® study, the Saudi Arabia NGS market is estimated to reach $50.0 million by 2031, growing at a CAGR of 10.1% between 2024 and 2031.
The rising number of cancer cases, rising pharmaceutical
R&D expenditures, and an increase in genome mapping studies are all driving
the growth of the Saudi Arabia NGS market. However, the high costs of NGS
systems and consumables, data confidentiality concerns, the availability of
alternative technologies, the low likelihood of detecting positive, actionable
biomarkers, and ethical and legal difficulties associated to NGS-based
diagnosis limit the growth of this industry.
Furthermore, increased adoption of NGS tools in hospitals
and clinical laboratories, as well as government efforts supporting large-scale
genome sequencing projects, are projected to provide potential possibilities
for market players. However, some of the constraints limiting market growth
include a dearth of experienced specialists, issues with data storage,
management, interpretation, and confidentiality, as well as worries about
regulatory requirements and consistency in diagnostic testing.
Key players in the Saudi Arabia NGS market include
Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche
Ltd. (Switzerland), Revvity, Inc. (US), QIAGEN N.V. (Netherlands), Agilent
Technologies, Inc. (US), Pacific Biosciences of California, Inc. (US), Danaher
Corporation (US), Oxford Nanopore Technologies Plc. (UK), Beijing Genomics
Institute (BGI) (China), and Bio-Rad Laboratories.
The Saudi Arabia NGS market is divided into four segments: Offering, Sequencing
Type, Application, and End User.
In 2024, the consumables category is estimated to dominate
the Saudi next-generation sequencing (NGS) market, accounting for 62.6%. This
category contains both sample preparation and sequencing consumables. Library
preparation and target enrichment solutions are expected to dominate the sample
preparation market, accounting for 45%. These methods are critical for
optimizing the whole library generation process, from DNA fragmentation and
amplification to adapter ligation, enrichment, and barcoding. Their comprehensive
character has made them extremely popular in clinical and research settings.
Target enrichment, in example, allows researchers to focus on certain genes or
genomic areas, reducing sequencing time and cost by eliminating extraneous data
collection.
In terms of sequencing types, targeted genome sequencing is
expected to be the top choice by 2024. This technique has various advantages,
including reducing irrelevant genetic variation, which might confound clinical
interpretation. It is also a less expensive option to whole genome (WGS) or
whole exome sequencing (WES), particularly for big populations. Furthermore,
targeted sequencing is important in pharmacogenomics, as it aids in the
identification of gene-drug interactions and the development of extremely
precise, gene-specific medicines.
In terms of applications, research and other scientific
studies are estimated to account for 56.9% of the Saudi NGS market in 2024.
This broad category encompasses cancer research, genetic illness research, cell
and molecular biology, microbiology, infectious disease research, and
agricultural science. Cancer research is expected to be the most significant,
accounting for 49.4% of the category. This trend is being driven by the
increasing incidence of cancer, the urgent need for breakthrough treatment alternatives,
and the shift toward individualized medicines. NGS-based cancer tests have a
significant advantage: they can replace several individual gene testing by
assessing a diverse set of actionable indicators in a single run, saving time
and resources.
Hospitals and diagnostic laboratories are expected to be the
major customers of NGS technologies in Saudi Arabia by 2024. These institutions
have greatly increased their usage of sequencing for clinical diagnostics, and
this trend is projected to continue as the cost of NGS decreases. This
expansion is also backed by Saudi Arabia's Vision 2030, which focuses on
developing local genetic testing capabilities and updating diagnostic
infrastructure through digital transformation. These projects make advanced genetic
tools more available throughout the country's healthcare system.
Download Sample
Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=6002
Key Questions
Answered in the Report:
·
What is the revenue generated from the sales of NGS instruments,
consumables, and software in Saudi Arabia?
·
At what rate is the demand for NGS solutions & services projected to
grow for the next five to seven years?
·
What is the historical market size and growth rate for the Saudi Arabia
NGS market?
·
What are the major factors impacting the growth of the Saudi Arabia NGS
market?
·
What are the major opportunities for existing players and new entrants
in the market?
·
Which offering and end user segments are anticipated to create major
traction for market players?
·
What are the key trends in this market?
·
Who are the major players in the Saudi Arabia NGS market? What are their
specific offerings in this market?
·
What recent developments have taken place in the Saudi Arabia NGS
market? What are the impacts of these strategic developments on the market?
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments
Post a Comment